By Reuters Staff
2 Min Read
FILE PHOTO: The logo of Swiss drugmaker Novartis is pictured at the French company s headquarters in Rueil-Malmaison near Paris, France, April 22, 2020. REUTERS/Charles Platiau
ZURICH (Reuters) - Swiss drugmaker Novartis has signed a deal to make ingredients for Roche’s Actemra treatment that is being repurposed for people with COVID-19, the company said on Thursday.
The arrangement is the third transaction signed by Novartis following agreements with BioNTech and CureVac to make therapies for other firms to help fight the pandemic.
Actemra is a treatment for rheumatoid arthritis which is also being tested in various clinical trials to treat COVID-19 associated pneumonia.
Novartis agrees to make ingredients Roche s Actemra for COVID-19 patients | WSAU News/Talk 550 AM · 99 9 FM
wsau.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wsau.com Daily Mail and Mail on Sunday newspapers.
Novartis agrees to make ingredients Roche s Actemra for COVID-19 patients
metro.us - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from metro.us Daily Mail and Mail on Sunday newspapers.